Loomis, Sayles & Company
IONS icon

Loomis, Sayles & Company’s Ionis Pharmaceuticals IONS Stock Holding History

Loomis, Sayles & Company’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-146
Closed -$5K – 1021
2023
Q1 		$5K Sell
146
-198
-58% -$7.43K ﹤0.01% 911
2022
Q4 		$13K Buy
+344
New +$14.5K ﹤0.01% 777
2014
Q1 		– Sell
-23,546
Closed -$938K – 756
2013
Q4 		$938K Buy
+23,546
New +$839K ﹤0.01% 626

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Loomis, Sayles & Company's IONS Position: Q2 2023 in Review

Loomis, Sayles & Company sold out of Ionis Pharmaceuticals (IONS) in Q2 2023, closing a stake of 146 shares — an estimated $5K sold.

Loomis, Sayles & Company first reported a position in IONS in Q4 2013 and held it in 3 quarters. The position peaked at $938K in Q4 2013. 304 funds tracked by Wall St. Rank hold IONS as of Q2 2023.

  • Loomis, Sayles & Company reported no remaining Ionis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Loomis, Sayles & Company sold 146 Ionis Pharmaceuticals shares in Q2 2023, an estimated $5K.
  • Loomis, Sayles & Company first reported a position in Ionis Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Loomis, Sayles & Company's Ionis Pharmaceuticals position peaked at $938K in Q4 2013.
  • 304 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2023.

Based on Loomis, Sayles & Company's 13F filing for Q2 2023, filed 11 Aug 2023.